版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
東西方肝癌的分析比較本文檔共40頁(yè);當(dāng)前第1頁(yè);編輯于星期五\22點(diǎn)4分Asian(n=342)Non-Asian(n=1350)ProportionsurvivingTime(months)0.01.00.80.60.40.202468101214160246810121416GefitinibPlaceboImportanceofEthnicityforMTA
─thelessonsofISELtrial本文檔共40頁(yè);當(dāng)前第2頁(yè);編輯于星期五\22點(diǎn)4分EGFRmutationratesineachsubgroupStudyCentreNo.ofpatientsAdenoCa(+BAC)(%)M(%)F(%)Smokers(%)n-smokers(%)Taiwan1NTUH624925612956Taiwan2VGH-T3767.452724469Korea3SeoulNU90219331326Japan4NCCTokyo666153693568Japan5AichiCCH596444704271HK6ChineseU7232————China7PekUMCH7648.632.334.8——Italy8*UChieti37510630725Shihetal,IJC2005Chouetal,CCR2005Hanetal,JCO2005Takanoetal,JCO2005*onlyAdenoCaMitsudomietal,JCO2005Lungetal,PAACR2005Muetal,CCR2005Machettietal,JCO2005本文檔共40頁(yè);當(dāng)前第3頁(yè);編輯于星期五\22點(diǎn)4分LiverCancerintheWorld
FerlayJetal.IARCPress,2001.Men(396,364)/Women(165,972)NorthAmerica(%)2.07/2.61Central&SouthAmerica(%)2.09/4.33Africa(%)6.90/8.69Europe(%)8.21/10.45Asia(%)81.54/74.13Oceania(%)0.25/0.27本文檔共40頁(yè);當(dāng)前第4頁(yè);編輯于星期五\22點(diǎn)4分GeographicdifferencesintheresultsofclinicaltrialsforadvancedHCC本文檔共40頁(yè);當(dāng)前第5頁(yè);編輯于星期五\22點(diǎn)4分Sorafenib
Median:46.3weeks(10.7mo)
(95%CI:40.9,57.9)SurvivalProbabilityWeeksHazardratio(S/P):0.69(95%CI:0.55,0.88)
P=0.00058*Placebo
Median:34.4weeks(7.9mo)
(95%CI:29.4,39.4)1.0000.750.500.250808162432404856647202742412051611086738120Patientsatrisk
Sorafenib:027622417912678472572Placebo:299303PhaseIIISHARPTrial
Overallsurvival(Intention-to-treat)LlovetJetal,
NEnglJMed.2008Jul24;359(4):378-90
(7.9mo)本文檔共40頁(yè);當(dāng)前第6頁(yè);編輯于星期五\22點(diǎn)4分ComparisonofTx(-)ControlArmsP’tNoMedianOSPVTTNMStageIVOkudaStageIIIECOGIII/IVSpain10217M23.5%54.9%0%*0%*HK1063M60.0%90.6%14%13%*Spanishtrialsexcluded“End-stagedisease”LlovetJM,Hepatology1999;29:62-7YeungYP,AmJGastroenterol2005;100:1995-2004EASTVSWEST本文檔共40頁(yè);當(dāng)前第7頁(yè);編輯于星期五\22點(diǎn)4分Randomizedtrials-octreotidevsplacebo本文檔共40頁(yè);當(dāng)前第8頁(yè);編輯于星期五\22點(diǎn)4分StudySchemaofSHARPandAPStudiesSorafenib400mgbidPlaceboEligibilityAdvancedHCCECOG0-2Child-PughANopriorsystemictherapyStratificationMacroscopicvascularinvasion(portalvein)and/orextrahepaticspreadECOGPSGeographicareaRANDOMIZE本文檔共40頁(yè);當(dāng)前第9頁(yè);編輯于星期五\22點(diǎn)4分PhaseIIISHARPandAsia-PacificOverallSurvivalSorafenib
Median:10.7months
(95%CI:40.9,57.9)SurvivalProbabilityMonthsHazardratio(sor/pla):0.69
(95%CI:0.55,0.87)
P=0.00058*Placebo
Median:7.9months
(95%CI:29.4,39.4)1.0000.750.500.2502024681012141618SurvivalProbabilitySorafenib
Median:6.5months
(95%CI:5.6-7.6)Placebo
Median:4.2months
(95%CI:3.7-5.5)HR(S/P):0.68P=0.0140.250.500.751.0000Months248101214162022618LlovetJM,etal.NEnglJMed2008:359:378-90
ChengAL,etal.ASCO2008,Abstract4509.
SHARPAsia-Pacific本文檔共40頁(yè);當(dāng)前第10頁(yè);編輯于星期五\22點(diǎn)4分Asia-PacificLiverCancerStudyvsSHARP:
BaselinePatientCharacteristicsAsia-Pacific
(N=226)SHARP1
(N=602)Medianage(range),years51(23-86)67(21-89)Hepatitisvirusstatus(HBV/HCV),%73/818/28Sex(Male),%8587ECOGPS(0/1/2),%26/69/5 54/38/8Macroscopicvascularinvasion,%3538Extrahepaticspread,%6951BCLCStage(B/C),%4/9617/82No.oftumorsites,%111442353132012≥43513Sitesofdisease,% Lung5021 Lymphnode32261LlovetJ,etal.NEnglJMed2008:359:378-90
.本文檔共40頁(yè);當(dāng)前第11頁(yè);編輯于星期五\22點(diǎn)4分LlovetJMetal.Lancet.2003;362:1907-1917.EndStageAdvancedStageIntermediateStageEarlyStageSurgicalTreatmentsLocalAblationNewAgentsTACEHCC(30%)Potentiallycurativetreatments5-yrsurvival:50-70%(50-60%)Randomizedtrialsmediansurvivalifuntreated:6-16mo(10%)BSCsurvival<3moHCCtreatmentschedule(BCLC)本文檔共40頁(yè);當(dāng)前第12頁(yè);編輯于星期五\22點(diǎn)4分Meta-analysisofPhaseIIIclinicalTrialsofHCCDatabasesMedline,Cancerlit,CochraneDatabaseofSystematicReviews,CochraneCentralRegisterofControlledTrials,DatabaseofAbstractsofReviewsofEffect,andASCOProceedings,2005–2007Articles/abstractspublishedJan1996toJun2007TrialsregisteredatthathavecompletedpatientrecruitmentKeywords:‘Hepatocellularcarcinoma’OR‘livercancer’OR‘HCC’‘Randomizedcontrolledtrial’OR‘randomizedcontrolledstudy’InclusioncriteriaRandomizedcontrolledtrialsofsystemictherapyforHCCpatientswhowerenotresectableandnotsuitableforlocaltherapy(TACE,PEIT,etc.)Placebo/supportivecareasthecontrolarm本文檔共40頁(yè);當(dāng)前第13頁(yè);編輯于星期五\22點(diǎn)4分Meta-regression:Predictorsofsurvivalofthecontrolgrouppatients(1)VariablesNParameterestimateSETPvalueIntercept113.145960.7443024.2267250.003904ChildA%110.033530.0097333.4450430.010763HBV%110.050190.0167462.9970640.020025Asian11-5.704470.983315-5.801270.000663R2=0.6463.571.88monthsinAsiantrials
5.961.46monthsinnon-Asiantrials.P=0.02ThemeanSDofthemedianoverallsurvivaltimewas
本文檔共40頁(yè);當(dāng)前第14頁(yè);編輯于星期五\22點(diǎn)4分HCCPS0-2,ChildAorBPS>2orChildCPVT(-)PVT(+)Single2or3,3cm4,3cmICGgood*ICGbad*ResectionAblation,Transplan-tationTACEMainPV(-),extra-hepaticspread(-)MainPV(+)orextra-hepaticspread(+)TACEBSCNewagentsBSCBil.2mg/dlBil.2mg/dlBil.2mg/dlBil.2mg/dlEarlystage(singleor3nodules3cm,PS0)Intermediatestage(multi-nodular,PS0)Advancedstage(portalinvasion,N1,M1,PS1-2Terminalstage(PS>2,ChildC)NTUHpracticeBCLCguidelineResectionAblation,Transplan-tationTACENewagentsBSCSingle,PH(-)Multiple,PH(+)本文檔共40頁(yè);當(dāng)前第15頁(yè);編輯于星期五\22點(diǎn)4分MakuuchiM.etal,HepatologyResearch2007JapanGuidelineEmbolizationhepaticarterialinfusionchemotherapy本文檔共40頁(yè);當(dāng)前第16頁(yè);編輯于星期五\22點(diǎn)4分GeographicdifferencesintheetiologyofHCCimplicationinthedevelopmentofMTAs本文檔共40頁(yè);當(dāng)前第17頁(yè);編輯于星期五\22點(diǎn)4分EtiologyofHCC
—DistinctGeographicDistribution
RiskFactorsHepatitisBvirusHepatitisCvirusAlcoholTobaccoOralcontraceptivesAflatoxinOtherandemergingriskfactors/cofactors
EstimateRange22 4~-5860 12~72458~5712 0~14---10~50
Limitedexposure<5---
EstimateRange20 18~-4463 48~942015~3340 9~51
--- ---
Limitedexposure--- ---
EstimateRange60 40~9020 9~56---11~4122 ---8---
Importantexposure<5 ---BoschFXetal.Gastroenterology2004;127:S5-16.EuropeandUnitedStates(%)Japan(%)AsiaandAfrica(%)本文檔共40頁(yè);當(dāng)前第18頁(yè);編輯于星期五\22點(diǎn)4分IsHBV-relatedHCCamoreaggressivetumor?IsHBV-relatedHCCassociatedwithmolecularchangeswhichaffectmoleculartherapy?HBV-relatedHCC本文檔共40頁(yè);當(dāng)前第19頁(yè);編輯于星期五\22點(diǎn)4分HCC─EastvsWestLong-termresultsaftersurgicaltreatmentweresimilarinWestandEastwhenclinicopatnologicfactorswereaccountedfor.PawlikTMetalLiverTransplantation2004;10(suppl1)74-80TaeckDetalLiverTransplantation2004;10(suppl1)58-63
本文檔共40頁(yè);當(dāng)前第20頁(yè);編輯于星期五\22點(diǎn)4分HBVvs.HCVHCC
ItalianLiverCancergroupSurvivalinpatientswithadvancedHCC.HBV-HCCpatientshadalowersurvivalthanHCV-HCCpatients(p=0.025)PatientswithHBV-HCCtendedtohavepoorprognosis;~CantariniMCetal:AmJGastroenterol2006;101:91-8.
andthedifferencebecamestatisticallysignificantamongpatientswithadvancedHCC本文檔共40頁(yè);當(dāng)前第21頁(yè);編輯于星期五\22點(diǎn)4分HBVvs.HCVHCCinNTUH
Survivalforpatientswithadvancedds.927patientsreceivingsupportivecareorchemotherapy.EtiologyMedian survival(M)1year(%)3year(%)5year(%)10year(%)HBV2.512.43.40.80.5HCV3.421.78.52.21.1B+C3.410.83.11.50NBNC2.611.23.11.01.0HCV+HCV-HCCpatientshadbettersurvivalthanHBV-HCCpatientsChenCHetal.
EurJCancer.2006Oct;42(15):2524-9.Epub2006Aug22本文檔共40頁(yè);當(dāng)前第22頁(yè);編輯于星期五\22點(diǎn)4分IsHBV-relatedHCCamoreaggressivetumor?IsHBV-relatedHCCassociatedwithmolecularchangesthatwillaffectmoleculartherapy?HBV-relatedHCC本文檔共40頁(yè);當(dāng)前第23頁(yè);編輯于星期五\22點(diǎn)4分HBV-vs.HCV-associatedHCC
—GenomicsandProteomicsIizukaNetal.CancerRes2002;62:3939-44.KimWetal.ClinCancerRes2003;9:5493-500.HBVandHCVcausehepatocarcinogenesisbydifferentmechanisms.TheexpressionpatternofproteomeinHCCtissuesiscloselyassociatedwithetiologicfactors本文檔共40頁(yè);當(dāng)前第24頁(yè);編輯于星期五\22點(diǎn)4分ViralProteinsAndSignalTransductionPathwaysHCVcoreHCVcoreByHsuC,ShenYC,ChengAL本文檔共40頁(yè);當(dāng)前第25頁(yè);編輯于星期五\22點(diǎn)4分TranscriptomeclassificationofHCC~BoyaultSetal:Hepatol2007;45:42.basedon120surgicallyresectedHCC,includingtranscriptomeanalysison57HCCsand3adenomas,andqRT-PCRvalidationinadditional63HCCs26本文檔共40頁(yè);當(dāng)前第26頁(yè);編輯于星期五\22點(diǎn)4分MolecularEpidemiologyofHBV
—notallHBVsarethesameGenotypeCisassociatedwithanincreasedriskofHCCinTaiwan.(OR=5.11)
YuMWetal.JNatlCancerInst2005;97:265-72.GenotypeAHBVhasagreaterhepatocarcinogenicpotentialinsub-saharanAfricans.
KewMCetal.JMedVirol2005;75:513-21.GenotypeBisassociatedwithlessdecompensatedlivercirrhosisthangenotypeA,C,orDinUSA.
ChuCJetal.Gastroenterology2003;125:444-51.本文檔共40頁(yè);當(dāng)前第27頁(yè);編輯于星期五\22點(diǎn)4分SorafenibphaseIIHCCstudy
HCV-vs.HBV-relatedHCCP’tNo.MedianageRace(%) CaucasiansClinicalbenefit(%)PFS(median,M)TTP(median,M)OS(median,M)HCV+337182756.56.512.4HBV+136654533.547.3~Huitzil-MelendezFDetal:ASCO-2007GISymposiumAbstract#173.AretrospectiveanalysisP
.27.05.29本文檔共40頁(yè);當(dāng)前第28頁(yè);編輯于星期五\22點(diǎn)4分Sub-groupanalysisoftheSHARPtrialHCV1Alcohol2PS3MVI/EHS4(178)(159)0(325)1-2(277)-(421)+(181)OSSorafenib14.010.313.38.914.58.9(m)Placebo7.98.08.85.610.26.7HR0.58(0.37-0.91)0.76(0.50-1.16)0.68(0.50-0.95)0.71(0.52-0.96)0.52(0.35-0.85)0.77(0.60-0.99)TTPSorafenib7.65.55.55.39.64.1(m)Placebo2.83.92.92.84.32.7HR0.44(0.25-0.76)0.64(0.40-1.03)0.55(0.40-0.77)0.61(0.42-0.88)0.40(0.23-0.70)0.64(0.48-0.84)1.BolondiL,etal.Abstract129.PosterandoralpresentationatASCO-GI;Orlando,FL;January2008.
2.CraxiA,etal.Posterpresentation.Chicago.USA3.RaoulJ,etal.JClinOncol.2008;25:abstract4587.4.ShermanM,etal.JClinOncol.2008;25:abstract4584.本文檔共40頁(yè);當(dāng)前第29頁(yè);編輯于星期五\22點(diǎn)4分ThalidomidephaseIIHCCstudy
HCV-vs.HBV-relatedHCCP’tNo.MedianageObjectiveresponse+ AFPresponse(%)TTP(median)OS(median)HCV+3367.527.314.1W32.6WHBV+6153.613.18.3W21.4W~HsuCetal:Proc.ASCO2004:Abs#4198.P61<.001.09.03.08本文檔共40頁(yè);當(dāng)前第30頁(yè);編輯于星期五\22點(diǎn)4分GeographicfactorsshouldbetakenintoconsiderationintheinterpretationanddesignofclinicaltrialsofadvancedHCC.本文檔共40頁(yè);當(dāng)前第31頁(yè);編輯于星期五\22點(diǎn)4分PhaseIIstudyofbevacizumab+capecitabineinpatientswithadvanced/metastatichepatocellularcarcinomaHsuC-H1,YangT-S2,HsuC1,TohHC3,EpsteinR4,
HsiaoL-T5,LinZ-Z1,ChengA-L1
(ProcAmSocClinOncol2008:26;#4603)本文檔共40頁(yè);當(dāng)前第32頁(yè);編輯于星期五\22點(diǎn)4分MedianOS:5.9M(95%CI:4.1-9.7)MedianPFS:2.7M(95%CI:1.5-4.1)Bevacizumabpluscapecitabine
foradvancedHCCOSMedian:5.9M(95%CI:4.1-9.7)PFSMedian:2.7M(95%CI:1.5-4.1)~HsuCHetal:ProcASCO2008:Abstract#4603.
本文檔共40頁(yè);當(dāng)前第33頁(yè);編輯于星期五\22點(diǎn)4分Worldwide,multicenter,open-label, 1,200ptswithadvancedHCCStratifyGeographicRegionPriorTACETumorInvasionRandomize1:1Sunitinib37.5mg,qdaslongasclinicalbenefitSorafenib400mg,bidaslongasclinicalbenefitSTUDYA6181170
AMULTI-NATIONAL,RANDOMIZED,OPEN-LABEL,PHASEIIISTUDYOFSUNITINIBVERSUSSORAFENIBINPATIENTSWITHADVANCEDHEPATOCELLULARCARCINOMA本文檔共40頁(yè);當(dāng)前第34頁(yè);編輯于星期五\22點(diǎn)4分ConclusionSignificantgeographicdifferencesinclinicalpracticeandetiologyareobservedinHCC.Thesedifferencessignificantl
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025年度企業(yè)財(cái)務(wù)預(yù)算編制與分析聘用合同版3篇
- 2025年度抵頂房屋租賃合同終止條件及抵頂協(xié)議3篇
- 2025年度年度養(yǎng)牛產(chǎn)業(yè)養(yǎng)殖廢棄物處理設(shè)施運(yùn)營(yíng)合同3篇
- 二零二五年度農(nóng)村住宅施工合同糾紛調(diào)解與仲裁代理服務(wù)合同
- 2025年度XX污水處理廠污泥處置與土地利用合同
- 2024年美縫施工與家居建材配送合同3篇
- 2024年種植業(yè)用簡(jiǎn)易大棚租賃合同書版B版
- 二零二五年兼職環(huán)境監(jiān)測(cè)工程師合同范本3篇
- 2024年度幼兒園校車司機(jī)應(yīng)急響應(yīng)能力培訓(xùn)聘用合同3篇
- 2025年度智能板梁吊裝與現(xiàn)場(chǎng)監(jiān)控系統(tǒng)合同2篇
- 2025年初級(jí)會(huì)計(jì)職稱《經(jīng)濟(jì)法基礎(chǔ)》全真模擬及答案(解析3套)
- 《健康社區(qū)評(píng)價(jià)標(biāo)準(zhǔn)》
- 戶外市場(chǎng)研究報(bào)告-魔鏡洞察-202412
- 浙江省金華市金東區(qū)2023-2024學(xué)年九年級(jí)上學(xué)期語(yǔ)文期末試卷
- ISO 56001-2024《創(chuàng)新管理體系-要求》專業(yè)解讀與應(yīng)用實(shí)踐指導(dǎo)材料之2:“1至3章:范圍、術(shù)語(yǔ)和定義”(雷澤佳編制-2025B0)
- (2021)最高法民申5114號(hào)凱某建設(shè)工程合同糾紛案 指導(dǎo)
- 【9物(人)期末】安慶市宿松縣2023-2024學(xué)年九年級(jí)上學(xué)期期末考試物理試題
- 導(dǎo)航通信一體化考核試卷
- 甘肅省會(huì)寧二中2025屆高考仿真模擬數(shù)學(xué)試卷含解析
- 2024年未成年子女房產(chǎn)贈(zèng)與協(xié)議
- 2024-2030年中國(guó)共模電感環(huán)形鐵芯行業(yè)發(fā)展?fàn)顩r規(guī)劃分析報(bào)告
評(píng)論
0/150
提交評(píng)論